NVS: 6-K company filing

6-K 1 f6k_061126.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 or 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 Report on Form 6-K dated June 11, 2026 (Commission File No. 1-15024) ____________________ Novartis AG (Name of Registrant) Lichtstrasse 35 4056 Basel Switzerland (Address of Principal Executive Offices) ____________________ Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F: ☒ Form 40-F: ☐ Novartis International AG CH-4002 Basel Switzerland https://www.novartis.com https://x.com/novartisnews PRESS RELEASE Novartis delpacibart braxlosiran (del-brax) Phase I/II study in f acioscapulohumeral muscular dystrophy (FSHD) meets primary biomarker endpoint Ad hoc announcement pursuant to Art. 53 LR · FORTITUDE study met primary and key secondary endpoints of reduction in KHDC1L and creatine kinase levels, with safety profile consistent with previous results · Del-brax indicates potential to become the first disease-modifying treatment for FSHD, a progressive and irreversible neuromuscular disease affecting approximately 45-87k people in the US and EU · Novartis plans to engage global regulatory authorities on Phase I/II data; Phase III study currently enrolling Basel, June 11, 2026 – Novartis announced today that the biomarker cohort of the FORTITUDE Phase I/II study of del-brax met its primary and key secondary endpoints, with reductions in KHDC1L (cDUX) and creatine kinase biomarker levels indicating both strong target engagement and reduction in muscle damage in patients with f acioscapulohumeral muscular dystrophy (FSHD). Del-brax is an investigational antibod